Literature DB >> 16306362

Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver.

Guenther Boden1, Pengxiang She, Maria Mozzoli, Peter Cheung, Kiranmai Gumireddy, Prekumar Reddy, Xiaqin Xiang, Zhijan Luo, Neil Ruderman.   

Abstract

To study mechanisms by which free fatty acids (FFAs) cause hepatic insulin resistance, we have used euglycemic-hyperinsulinemic clamping with and without infusion of lipid/heparin (to raise or to lower plasma FFAs) in alert male rats. FFA-induced hepatic insulin resistance was associated with increased hepatic diacylglycerol content (+210%), increased activities of two serine/threonine kinases (protein kinase C-delta and inhibitor of kappaB [IkappaB] kinase-beta), increased activation of the proinflammatory nuclear factor-kappaB (NF-kappaB) pathway (IkappaB kinase-beta, +640%; IkappaB-alpha, -54%; and NF-kappaB, +73%), and increased expression of inflammatory cytokines (tumor necrosis factor-alpha, +1,700% and interleukin-1beta, +440%) and plasma levels of monocyte chemoattractant protein-1 (+220%). We conclude that FFAs caused hepatic insulin resistance, which can produce overproduction of glucose and hyperglycemia, and initiated inflammatory processes in the liver that could potentially result in the development of steatohepatitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306362     DOI: 10.2337/diabetes.54.12.3458

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  170 in total

Review 1.  The role of lipid droplets in metabolic disease in rodents and humans.

Authors:  Andrew S Greenberg; Rosalind A Coleman; Fredric B Kraemer; James L McManaman; Martin S Obin; Vishwajeet Puri; Qing-Wu Yan; Hideaki Miyoshi; Douglas G Mashek
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

2.  Oestrogen alters adipocyte biology and protects female mice from adipocyte inflammation and insulin resistance.

Authors:  R E Stubbins; K Najjar; V B Holcomb; J Hong; N P Núñez
Journal:  Diabetes Obes Metab       Date:  2011-11-22       Impact factor: 6.577

3.  Differential effects of hypothalamic long-chain fatty acid infusions on suppression of hepatic glucose production.

Authors:  R A Ross; L Rossetti; T K T Lam; G J Schwartz
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-07-20       Impact factor: 4.310

Review 4.  Vascular repair strategies in type 2 diabetes: novel insights.

Authors:  Kira Kuschnerus; Ulf Landmesser; Nicolle Kränkel
Journal:  Cardiovasc Diagn Ther       Date:  2015-10

Review 5.  Central nervous system and control of endogenous glucose production.

Authors:  Giovanna Demuro; Silvana Obici
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

6.  Non-alcoholic fatty liver disease is an independent risk factor for inflammation in obstructive sleep apnea syndrome in obese Asian Indians.

Authors:  Surya Prakash Bhatt; Randeep Guleria; Naval K Vikram; A K Gupta
Journal:  Sleep Breath       Date:  2018-07-22       Impact factor: 2.816

7.  Monitoring FoxO1 localization in chemically identified neurons.

Authors:  Makoto Fukuda; Juli E Jones; David Olson; Jennifer Hill; Charlotte E Lee; Laurent Gautron; Michelle Choi; Jeffrey M Zigman; Bradford B Lowell; Joel K Elmquist
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

8.  Effects of hyperinsulinemia on hepatic metalloproteinases and their tissue inhibitors.

Authors:  Guenther Boden; Weiwei Song; Karen Kresge; Maria Mozzoli; Peter Cheung
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-29       Impact factor: 4.310

Review 9.  Obesity and vulnerability of the CNS.

Authors:  Annadora J Bruce-Keller; Jeffrey N Keller; Christopher D Morrison
Journal:  Biochim Biophys Acta       Date:  2008-10-17

Review 10.  Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity.

Authors:  W Timothy Garvey; Jeffrey I Mechanick
Journal:  Obesity (Silver Spring)       Date:  2020-03       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.